Calidi Biotherapeutics, Inc.: net property, plant and equipment
Net property, plant and equipment for Calidi Biotherapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Calidi Biotherapeutics, Inc. financial histories
What this measure means
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2022-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 781,000 | USD | 2026-03-27 | 10-K · 0001493152-26-013242 |
| At date | 2024-12-31 | 869,000 | USD | 2026-03-27 | 10-K · 0001493152-26-013242 |
| At date | 2023-12-31 | 1,270,000 | USD | 2025-03-31 | 10-K · 0001641172-25-001810 |
| At date | 2022-12-31 | 887,000 | USD | 2024-03-15 | 10-K · 0001493152-24-010158 |
Related financial histories
- Calidi Biotherapeutics, Inc.: total assets
- Calidi Biotherapeutics, Inc.: total liabilities
- Calidi Biotherapeutics, Inc.: stockholders equity
- Calidi Biotherapeutics, Inc.: net income or loss
- Calidi Biotherapeutics, Inc.: operating cash flow
- Calidi Biotherapeutics, Inc.: financing cash flow
- Calidi Biotherapeutics, Inc.: investing cash flow
- Calidi Biotherapeutics, Inc.: retained earnings or deficit
- Calidi Biotherapeutics, Inc.: basic weighted-average shares
- Calidi Biotherapeutics, Inc.: diluted weighted-average shares
- Calidi Biotherapeutics, Inc.: basic earnings per share
- Calidi Biotherapeutics, Inc.: diluted earnings per share
- Calidi Biotherapeutics, Inc.: income tax expense or benefit
- Calidi Biotherapeutics, Inc.: share-based compensation expense
- Calidi Biotherapeutics, Inc.: operating income or loss
- Calidi Biotherapeutics, Inc.: current assets
- Calidi Biotherapeutics, Inc.: current liabilities
- Calidi Biotherapeutics, Inc.: operating expenses
- Calidi Biotherapeutics, Inc.: selling, general and administrative expense
- Calidi Biotherapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Calidi Biotherapeutics, Inc. / CIK 0001855485
- Captured
- 2026-09-21T17:32:59.369Z
- SEC response SHA-256
cee5bcb17267f2683b0e32bc7855962df8b75eaa8e203dfe43552815b3a9182b
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001855485.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))